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INTRODUCTION
Post-transplant lymphoproliferative disease (PTLD) is a serious, 
often fatal complication after solid organ transplantation1). The 
incidence of PTLD is greatest among heart (2∼13%), lung 
(12%), and heart/lung (5∼9%) transplant recipients, but occurs 
less frequently in liver (2%), renal (1∼3%), and bone marrow 
(1∼2%) transplant recipients2-4).
The patient's age, transplanted organ, Epstein-Barr virus 
(EBV) status of the donor and recipient before transplantation 
and the dosage of immunosuppressive drugs are considered 
risk factors1, 5). These differences in the incidence of PTLD may 
be partly attributed to the higher doses of immunosuppressive 
drugs necessary following heart and lung transplantation4). 
Other possible contributing factors may be bronchus-associated 
lymphoid tissue (BALT) and nodal tissue harboring EBV in the 
donor transplant. EBV infection, either preexisting in the 
recipient or acquired from the donor, is strongly implicated in 
the pathogenesis of PTLD4, 6). Immunosuppression may permit 
uncontrolled proliferation of EBV-stimulated B cells by inhibition 
of suppressor T cells, from polyclonal to monomorphic and 
monoclonal proliferations. Monoclonal proliferations can subse-
quently accrue mutations of oncogenes or tumor suppressor 
genes, and lead to gain a fully malignant behavior and loss of 
responsiveness to immune regulation. Moreover, mutation of 
c-myc, N-ras and p53 genes has recently been implicated in 
the terminal progression of PTLD3, 7). 
The peak incidence of PTLD occurs 3 to 4 months after 
transplantation, but may develop as early as 6 days later.  
Patients with early onset PTLD, within the first year, have a 
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better prognosis than those with one developed late onset1). In 
lung transplant recipients, PTLD may develop in the allograft 
lung, lymph nodes or other MALT sites, which frequently 
involves extranodal locations, including the lung. A lung involved 
by PTLD may present as nodular or diffuse reticulonodular 
infiltrates, as solitary or multiple lung masses, or as hilar and 
mediastinal lymphadenopathy8), and pulmonary nodules often 
have foci of necrosis. Histologically, PTLD can range from 
polymorphic B cell hyperplasia to monomorphic B-cell proli-
feration that is indistinguishable from diffuse large cell or 
immunoblastic lymphomas3, 5). These lymphomas are generally 
high grade with diffuse large cell, immunoblastic, or small 
noncleaved cell Burkitt or Burkitt-like morphologies. 
Herein, our experience of two recently encountered cases of 
PTLD following a lung transplantation, which demonstrated an 
aggressive clinical behavior, is reported, with a review of the 
literature.  
CASE REPORT
Case 1.
A 42-year-old man was admitted with a fever and chills for 
3 days. His past medical history included dyspnea on exertion, 
which had developed from childhood, and was diagnosed as 
having a large patent ductus arteriosus with Eisenmenger 
syndrome at the age of 20. Six months prior to this presentation, 
the patient had undergone heart-lung transplantation due to 
progressive dyspnea, chest pain and peripheral cyanosis. His 
preoperative examination revealed cytomegalovirus (CMV) IgM 
Figure 1. A plain chest radiograph (A) and a computerized tomograph (B, C) of case 1, revealing multiple, variably sized 
nodular lesions in both upper lung fields. Multiple mediastinal lymphadenopathies are also shown in the right lobe 
paratracheal and subcarinal areas. Microscopic findings of a transthoracic lung biopsy show irregular thickening of the 
alveolar septa and perivascular connective tissue, due to the diffuse infiltration of atypical lymphoid cells, which were 
confirmed as being of B-cell lineage by immunohistochemical staining (D, × 100 & × 200, H-E).
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antibody negative, CMV IgG antibody positive, Herpes simplex 
virus (HSV) IgM antibody negative, HSV IgG antibody positive, 
Varicella Zoster virus (VZV) IgM antibody negative and VZV 
IgG antibody positive. The tests for EBV early antigen (EA)-IgM 
was positive, EA-IgG negative and Epstein-Barr nuclear 
antigen (EANA) IgG positive. The donor was a 25-year-old 
male whose preoperative examination revealed CMV IgM 
antibody negative and CMV IgG antibody positive. The test for 
EBV EA-IgM was negative and EA-IgG positive. During the 
immediate postoperative period, the recipient suffered gastric ulcer 
perforation and underwent a subtotal gastrectomy and gastrojeju-
nostomy. Two months after the transplantation, he developed 
spiking fever with right lower lung field haziness and an 
accompanying pleural effusion, which was treated under the 
impression of bacterial pneumonia. One month later, he 
suffered a sudden fever and chill, and was admitted for further 
evaluation.
On physical examination, he had a chronic ill-looking 
appearance and a pale face. His chest examination revealed 
coarse breathing sounds in both lung fields and a grade I/IV 
systolic murmur in the aortic and tricuspid areas. Laboratory 
tests showed a white cell count of 11,090/μL, hemoglobin 9.2 
g/dL, platelet 315,000/μL, Wintrobe erythrocyte sedimentation 
rate (ESR) 5 mm/hr (reference range; 0-10 mm/hr), serum 
protein 5.1 g/dL, albumin 2.4 g/dL, aspartate aminotransferase 
(AST) / alanine aminotransferase (ALT) 22/21 IU/L (reference 
range; <37/<43 IU/L, respectively), creatinine 0.8 mg/dL, CMV 
IgM antibody positive, CMV IgG antibody positive, urine 
CMV-PCR negative, HSV antibody IgM negative, HSV antibody 
IgG positive, VZV antibody IgM negative and VZV antibody IgG 
positive. The tests for EBV revealed EA-IgM antibody positive, 
EA-IgG antibody negative, EBNA IgG antibody positive and 
EBV-PCR negative. A plain chest radiograph and computerized 
tomography revealed multiple, variably sized nodular lesions at 
the apical segments of both upper lungs, anterior segment of 
the left lung, posterobasal segment of the left lower lobe, hilar 
portion of the right middle lobe and superior segment of the 
right lower lobe. Multiple mediastinal lymphadenopathies were 
also seen in the right paratracheal and subcarinal areas. 
Minimal pleural effusion was also observed in the right lower 
thorax. The other findings were unremarkable (Figure 1A-1C). 
A computed tomogram-guided transthoracic lung biopsy was 
performed. Irregular thickening of the alveolar septa and the 
perivascular connective tissue, due to diffuse infiltration of 
atypical lymphoid cells, were observed. These atypical lymphoid 
cells were confirmed as B-cell lineage by immunohistochemical 
staining. The EBV-DNA reaction was positive by in situ 
hybridization, but light chain restriction could not be confirmed 
(Figure 1D). 
Therefore, the patient was diagnosed with PTLD presenting 
as a polymorphic subtype. His immunosuppressant regimen 
was adjusted according to the diagnosis. Thirty days after 
admission, the patient began to complain of visual disturbance, 
and was treated with intravitreal ganciclovir and foscarnet under 
the diagnosis of CMV retinitis. The chest lesion continued to 
progress, with multiple infectious foci, and multiorgan failure 
developed. He died 42 days after admission. 
Case 2.
A 33-year-old woman was admitted for evaluation of 
multiple air space nodules in the left lung field. Seven years 
before this presentation, she began to suffer from progressive 
dyspnea and dry cough. Four years before presentation, she 
was transferred to a general hospital and diagnosed as having 
severe emphysema (FVC 1.34 L (35.0%), FEV1 0.61L/sec 
(20.0%), DLCO 53% of expected value). She was a healthy 
Hepatitis B virus (HBV) carrier and her α 1-antitrypsine levels 
were 189, 381 and 225.3 mg/dL, by three separate tests. Two 
years before presentation, she underwent left lung trans-
plantation and had been administered cyclosporine A, 
azathioprine and corticosteroid for immunosuppression, and 
lamivudine for HBV management. Preoperative serologic tests 
revealed CMV IgM antibody negative, CMV IgG antibody 
positive, HSV IgM antibody negative, HSV IgG antibody 
positive, VZV IgM antibody negative and VZV IgG antibody 
positive. EA-IgM antibody was positive and EA-IgG antibody 
negative. There was no information regarding the donor. During 
18 months of follow-up after the transplantation, she showed 
no signs of rejection or an infectious event. However, a routine 
follow up plain chest radiograph showed multiple air space 
nodules in the transplanted lung.
On physical examination, her body temperature, pulse and 
respiration rates were 36.2℃, 74/min and 20/min. She had a 
chronic ill-looking appearance and a moon face, although the 
lung sounds were clear in both lung fields without rales.  
Laboratory tests revealed a white cell count of 5,440/μL, 
hemoglobin 11.7 g/dL, platelet 232,000/μL, C-reactive protein 
(CRP) quantitation 25.9 (reference range; 0∼8 mg/L), Wintrobe 
ESR 58 mm/hr, serum protein 5.6 g/dL, albumin 3.2 g/dL, AST 
/ ALT 19/12 IU/L, BUN 33 mg/dL and creatinine 0.9 mg/dL. 
Urine analysis was normal and a tuberculosis skin test was 
negative. Serologic tests indicated that she was CMV IgM and 
IgG antibodies positive. A CMV PCR from bronchial washing 
fluid was negative.  The EA-IgM and IgG antibodies were 
positive, and the EBNA-IgG antibody was positive, which is a 
typical reactivity pattern for EBV reactivation, e.g. EBV- 
associated lymphoproliferative diseases or epithelial carcinomas, 
such as nasopharyngeal carcinoma. EBV-PCR using whole 
blood was negative. Chest high resolution computed tomogram 
revealed multiple air spaced nodules at the left upper lobe and 
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collapse of the lingular segment. These nodules had speculated 
margins with accompanying peripheral ground glass opacity, 
suggesting inflammatory changes (Figure 2A-2C). A comparison 
of inspiratory and expiratory phase images showed neither 
mosaic perfusion nor small airway disease. The native right 
lung showed emphysematous changes, with no interval change. 
A percutaneous transthoracic needle biopsy was performed on 
a nodule in the left upper lobe. These nodules consisted of 
lymphocytes, which by immunohistochemical study revealed 
positive reactions to L-26 and negative reactions to UCHL-1, 
Kappa, Lambda, cytokeratin and Ki-1 in the tumor cells. A 
malignant lymphoma, of high-grade large B-cell type, was 
confirmed (Figure 2D).
She was given a chemotherapeutic regimen comprising of 
cytoxan 1200 mg, vincristine 2 mg and prednisone 100 mg for 
5 days, and one-week later epirubicin 90 mg was administered 
before being discharged. Two weeks later the patient developed 
sudden dyspnea and died of pulmonary edema and a pneu-
mothorax.
DISCUSSION
The incidence of PTLD after lung transplantation is 2-fold 
higher than that seen after any other type of organ trans-
plantation1). Primary EBV infection has been implicated as the 
Figure 2. Radiograph of case 2 showing multiple air spaced nodules, which had speculated margins accompanied by 
peripheral ground glass opacity at the left upper lobe, with collapse of the lingular segment. The native right lung shows 
severe emphysematous changes (A, B, C). A percutaneous transthoracic needle biopsy specimen shows aggregation of 
lymphocytes, and an immunohistochemical study of these revealed a positive reaction to L-26, but negative reactions to 
UCHL-1, Kappa, Lambda, cytokeratin and Ki-1, suggesting a malignant lymphoma, which was later confirmed as a high 
grade B-cell type malignant lymphoma (D, × 100 & × 200, H-E).
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major risk factor for PTLD, particularly for EBV-naive patients 
who seroconverted after the lung transplantation9). A 20-fold 
increase in the risk of developing PTLD was reported to occur 
in EBV-seronegative vs EBV-seropositive lung recipients after 
transplantation10). In our cases, serologic EBV testing of the 
recipients showed that EA-IgM was positive and EA-IgG 
negative, suggesting a recent EBV infection prior to the 
transplantation.
In the local community, EBV spreads by contact with oral 
secretion, but has been transmitted by blood transfusion and 
bone marrow transplantation in a hospital setting through the 
EBV receptor (CD21), which present on the surface of B cells 
and epithelial cells.  The most likely source of EBV infection 
through solid organ transplantation is transmission through an 
organ from an EBV-positive to an EBV-seronegative recipient11). 
The exact mechanism by which the donor virus is transmitted 
from the transplanted organ to the recipient is unknown, 
although in solid organ transplant recipients, virus-infected cells 
in PTLD of recipient origin have been identified12). Thus, the 
donor virus may either be transmitted in a cell-free state or 
released by donor cells in the recipient. A sufficient number of 
EBV-carrying B cells may remain in the blood within the 
allograft and pass into the circulation of the recipient; the virus 
would then enter the lytic cycle and infect the recipient B-cell 
population11). Alternatively, heart and lung tissue may contain 
foci of EBV-infected cells, which may act as sites of virus 
replication. EBV infection in a naive recipient, occurring in the 
setting of altered host immunity, leads to uncontrolled 
proliferation and transformation of recipient B cells infected with 
EBV. These possible patterns of events require identification of 
high-risk causes and the development of effective therapeutic 
modalities. A recent study found that continuous, specific 
anti-viral prophylaxis in high-risk EBV-seronegative recipients 
significantly reduced the incidence of PTLD after lung 
transplantation in the absence of induction therapy13). 
Lymphoid proliferations that are morphologically indisting-
uishable from a malignant lymphoma occur with greater 
frequency in organ transplant recipients than in the general 
population; but are unlikely to progress to malignant lymphomas 
in immunocompetent patients, but often regress if the 
immunosuppression is sufficiently reduced3, 5). Polymorphic B-cell 
hyperplasia is associated with a mixture of small lymphocytes, 
plasma cells and immmunoblasts, without significant cytologic 
atypia. These cases are usually polyclonal and respond to 
reduction of immunosuppression. Monomorphic PTLD has 
sheets of large transformed monoclonal cells or immunoblasts. 
Despite their overt malignant appearance, some monomorphic 
tumors regress after reduction of immunosuppression. Non- 
responders require chemotherapy, although they usually succumb 
to a progressive disease. Neither the histological appearance 
nor clonality can accurately predict the response to modulation 
of immunosuppression. Over the past decades, numerous 
attempts have been made to classify these lesions using 
morphology, immunohistochemistry and monoclonality, but none 
of these tools alone or in combination was found to accurately 
predict the biological behavior5, 7). Monoclonality is considered 
an adverse prognostic feature. However, some monoclonal 
PTLDs regress with reduced immunosuppression. Conversely, a 
subset of polyclonal lesions has a more aggressive course5). 
The first case was confirmed as polymorphic, and was treated 
by conservative means by adjusting the immunosuppressant 
and anti-viral agent used to treat the accompanying CMV 
infection, whereas the second case was suspected as 
monomorphic PTLD, and treated aggressively using a chemo-
therapeutic regimen, but did not respond to treatment.
Because PTLD treatments are most effective in the early 
stage, prior to the occurrence of progression of monomorphic 
or monoclonal proliferations2, 14), not only the early detection of 
PTLD, but also the identification of the clonality of PTLD, are of 
importance in planning the means of treatment. 
REFERENCES
1) Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, 
Nalesnik M, Hardesty RL, Dummer JS. Post transplant 
lymphoproliferative disease in thoracic organ transplant patients: ten 
years of cyclosporine-based  immunosuppression. J Heart Lung 
Transplant 10:877-886, 1991
2) Cohen JI. Epstein-Barr virus lymphoproliferative disease associated 
with acquired immunodeficiency. Medicine 70:137-160, 1991
3) Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose 
EA, Michler RE. Correlative morphologic and molecular genetic 
analysis demonstrates three distinct categories of post transplantation 
lymphoproliferative disorders. Blood 85:552-565, 1995
4) Montone KT, Litzky LA, Wurster A, Kaiser L, Bavaria J, Kotloff R, 
Palevsky H, Pietra GG, Tomaszewski JE. Analysis of Epstein-Barr 
virus-associated posttransplantation lymphoproliferative disorder after 
lung transplantation. Surgery 119:544-551, 1996 
5) Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham 
JA, Makowka L, Ho M, Locker J. The pathology of post transplant 
lymphoproliferative disorders occurring in the setting of cyclosporine 
A-prednisolne immunosuppression. Am J Pathol 133:173-192, 1988
6) Randhawa PS, Jaffe R, Demetris AJ, Nalesnik M, Starzl TE, Chen 
YY, Weiss LM. The systemic distribution of Epstein-Barr virus 
genomes in fatal PTLD: an in situ hybridization study. Am J Pathol 
138:1027-1033, 1991
7) Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors 
arising after organ transplantation. Am J Pathol 135:977-987, 1989
8) Bragg DG, Chor PJ, Murray KA, Kjeldsberg CR. Lymphoproliferative 
disorders of the lung: histopathology, clinical manifestations and 
imaging features. Am J Roentgenol 163:273-281, 1994
9) Hanto DW, Frizzera G, Gajl-Peczalska KJ, Sakamoto K, Purtilo DT, 
The Korean Journal of Internal Medicine: Vol. 19, No. 4, December, 2004282
Balfour HH Jr, Simmons RL, Najarian JS. Epstein-Barr virus- 
induced B-cell lymphoma after renal transplantation: acyclovir therapy 
and transition from polyclonal to monoclonal B-cell proliferation. N Engl 
J Med 306:913-918, 1982
10) Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy 
J. Post transplantation lymphoproliferative disorder in the Epstein- 
Barr naive lung transplant recipient. Am J Respir Crit Care Med 
154:1712-1717, 1996
11) Haque T, Thomas JA, Falk KI, Parratt R, Hunt BJ, Yacoub M, 
Crawford DH. Transmission of donor Epstein-Barr virus (EBV) in 
transplanted organs causes lymphoproliferative disease in EBV- 
seronegative recipients. J Gen Virol 77:1169-1172, 1996
12) Cen H, Breinig MC, Atchison RW, Ho M, McKnight JL. EBV 
transmission via the donor organ in solid organ transplantation: 
polymerase chain reaction and restriction fragment length polymorphism 
analysis of IR2, IR3 and IR4. J Virol 65:976-980, 1991
13) Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. 
Anti-viral prophylaxis reduces the incidence of lymphoproliferative 
disease in lung transplant recipients. J Heart Lung Transplant 21: 
547-554, 2002
14) Levine AM. AIDS-associated malignant lymphoma. Med Clin North 
Am 76:253-268, 1992 
